Showing results (11-20 of 90) with videos related to
Sort By:
Pageof 9
Journal of the Neurological Sciences|November 1, 1977
Histocompatibility types and measles antibodies in multiple sclerosisM E Fewster, L W Myers, G W Ellison, et al.Neurology|August 1, 1975
Oligodendroglial toxicity by serum and lymphocytes from patients with multiple sclerosisM E Fewster, G W Ellison, L W Myers, et al.Journal of Neuroimmunology|June 1, 1983
Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 1. Association between amount of prostaglandin produced, natural killer, and endogenous interferonJ E Merrill, R H Gerner, L W Myers, et al.Neurology|November 1, 1987
Evoked potentials predict the clinical changes in a multiple sclerosis drug studyM R Nuwer, J W Packwood, L W Myers, et al.Electroencephalography and Clinical Neurophysiology|January 1, 1988
A parametric scale for BAEP latencies in multiple sclerosisM R Nuwer, J W Packwood, G W Ellison, et al.International Journal of Immunopharmacology|January 1, 1991
Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: studies in patients with chronic progressive multiple sclerosisF Chiappelli, L W Myers, G W Ellison, et al.Advances in Alcohol & Substance Abuse|January 1, 1987
Delta-9-THC in the treatment of spasticity associated with multiple sclerosisJ T Ungerleider, T Andyrsiak, L Fairbanks, et al.Journal of Neuroscience Research|December 18, 2001
T-cell responses to oligodendrocyte-specific protein in multiple sclerosisT Vu, L W Myers, G W Ellison, et al.Journal of Neuroimmunology|March 1, 1987
Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parametersD J Moody, J Kagan, D Liao, et al.Neurology|July 1, 1988
Clinical drawbacks of total lymphoid irradiation: the consL W Myers, G W Ellison, J L Fahey, et al.Pageof 9